观点：长效抗胆碱能药物/长效β2受体激动剂联合治疗应作为慢性阻塞性肺疾病的初始维持治疗吗？应该。 - Suppr

Suppr

超能文献

POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes.

作者信息

Cazzola Mario, Matera Maria Gabriella

机构信息

Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy.

Unit of Pharmacology, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

出版信息

Chest. 2018 Oct;154(4):746-748. doi: 10.1016/j.chest.2018.06.022.

DOI:10.1016/j.chest.2018.06.022

PMID:30290925

Abstract

摘要

相似文献

POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes.观点：长效抗胆碱能药物/长效β2受体激动剂联合治疗应作为慢性阻塞性肺疾病的初始维持治疗吗？应该。

Chest. 2018 Oct;154(4):746-748. doi: 10.1016/j.chest.2018.06.022.

COUNTERPOINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? No.反对观点：长效抗胆碱能药物/长效β2受体激动剂联合治疗是否应用于慢性阻塞性肺疾病的初始维持治疗？答案是否定的。

Chest. 2018 Oct;154(4):749-751. doi: 10.1016/j.chest.2018.06.024.

Comparative Effectiveness of Long-Acting Beta -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.长效β受体激动剂联合长效毒蕈碱拮抗剂或吸入性糖皮质激素治疗慢性阻塞性肺疾病的比较疗效

Pharmacotherapy. 2017 Apr;37(4):447-455. doi: 10.1002/phar.1913.

Role of Long-Acting Muscarinic Antagonist/Long-Acting β-Agonist Therapy in Chronic Obstructive Pulmonary Disease.长效毒蕈碱拮抗剂/长效β受体激动剂疗法在慢性阻塞性肺疾病中的作用

Ann Pharmacother. 2017 Aug;51(8):696-705. doi: 10.1177/1060028017705149. Epub 2017 Apr 14.

Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.慢性阻塞性肺疾病患者吸入长效支气管扩张剂的心血管和脑血管安全性比较：一项基于人群的队列研究。

Pharmacotherapy. 2016 Jan;36(1):26-37. doi: 10.1002/phar.1684.

Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.来自七个拉丁美洲国家的慢性阻塞性肺疾病（COPD）患者使用的呼吸药物：LASSYC研究

Int J Chron Obstruct Pulmon Dis. 2018 May 11;13:1545-1556. doi: 10.2147/COPD.S154097. eCollection 2018.

Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.基于人群队列的研究：血嗜酸性粒细胞靶向 COPD 患者中 LABA-ICS 与 LAMA 作为初始治疗的比较效果。

Lancet Respir Med. 2018 Nov;6(11):855-862. doi: 10.1016/S2213-2600(18)30368-0. Epub 2018 Oct 18.

POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV < 50% Predicted) COPD? Yes.观点：对于所有病情稳定的慢性阻塞性肺疾病全球倡议（GOLD）3级（预计第一秒用力呼气容积[FEV]占预计值的30%≤FEV＜50%）患者，是否应尝试停用吸入性糖皮质激素？是。

Chest. 2018 Apr;153(4):778-782. doi: 10.1016/j.chest.2018.01.029. Epub 2018 Feb 21.

A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.一项回顾性研究，旨在评估新开始接受长效单药或联合治疗的慢性阻塞性肺疾病患者的临床特征及开始三联开放治疗的时间。

Int J Chron Obstruct Pulmon Dis. 2017 Jun 21;12:1825-1836. doi: 10.2147/COPD.S129007. eCollection 2017.

Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.在开始三联疗法（ICS/LAMA/LABA）治疗之前，COPD 患者的临床特征和用药模式：一项回顾性研究。

Respir Med. 2018 Sep;142:73-80. doi: 10.1016/j.rmed.2018.07.009. Epub 2018 Jul 17.

引用本文的文献

Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective.恩昔芬净联合长效毒蕈碱拮抗剂用于慢性阻塞性肺疾病：三功能双重支气管扩张视角

Drugs. 2025 Jul 24. doi: 10.1007/s40265-025-02213-w.

The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review.长效毒蕈碱拮抗剂/长效β受体激动剂固定剂量联合治疗在中国慢性阻塞性肺疾病中的作用：一项叙述性综述

J Thorac Dis. 2021 Nov;13(11):6453-6467. doi: 10.21037/jtd-21-961.

The Potential Role and Regulatory Mechanisms of MUC5AC in Chronic Obstructive Pulmonary Disease.黏蛋白 5AC 在慢性阻塞性肺疾病中的潜在作用及调控机制。

Molecules. 2020 Sep 27;25(19):4437. doi: 10.3390/molecules25194437.

Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials.格隆溴铵/富马酸福莫特罗定量吸入器用于慢性阻塞性肺疾病初治患者的维持治疗：随机 PINNACLE 试验的事后分析。

Respir Res. 2020 Mar 12;21(1):69. doi: 10.1186/s12931-020-1332-3.

Pharmacological treatment and current controversies in COPD.慢性阻塞性肺疾病（COPD）的药物治疗及当前争议

F1000Res. 2019 Aug 29;8. doi: 10.12688/f1000research.19811.1. eCollection 2019.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验